Mandate

Vinge has advised Ambea AB (publ) in connection with its refinancing

Vinge advised Ambea AB (publ), the leading care provider in Scandinavia, in connection with a refinancing in an aggregate amount of SEK 5,000,000,000.

On 31 October 2022 Ambea AB (publ) entered into an unsecured facility agreement with a bank syndicate comprised of three Nordic banks. The new facility agreement has an initial term of three years with a one year extension option and consist of a SEK 4,000,000,000 committed facility and an uncommitted accordion option of SEK 1,000,000,000.

The purpose of the facility agreement is to refinance certain outstanding loans under the previous SEK 4,500,000,000 facility agreement and to increase the Ambea group’s overall financial flexibility.

Vinges team consisted of partner Albert Wållgren together with Josefine Lanker and Sofia Haggren.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026